Statement of Retraction: Nesfatin-1 protects against diabetic cardiomyopathy in the streptozotocin-induced diabetic mouse model via the p38-MAPK pathway

Author unknown

Open source

DOI
10.1080/21655979.2026.2667569
Published
2026-05-21
Container
Bioengineered
Publisher
Informa UK Limited
Open access
unknown

Credibility signals

uncertain Score 58/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1080/21655979.2026.2667569,
  title = {Statement of Retraction: Nesfatin-1 protects against diabetic cardiomyopathy in the streptozotocin-induced diabetic mouse model via the p38-MAPK pathway},
  year = {2026},
  journal = {Bioengineered},
  doi = {10.1080/21655979.2026.2667569},
  url = {https://doi.org/10.1080/21655979.2026.2667569}
}

RIS

TY  - JOUR
TI  - Statement of Retraction: Nesfatin-1 protects against diabetic cardiomyopathy in the streptozotocin-induced diabetic mouse model via the p38-MAPK pathway
PY  - 2026
JO  - Bioengineered
DO  - 10.1080/21655979.2026.2667569
UR  - https://doi.org/10.1080/21655979.2026.2667569
ER  - 

APA

Statement of Retraction: Nesfatin-1 protects against diabetic cardiomyopathy in the streptozotocin-induced diabetic mouse model via the p38-MAPK pathway. (2026). Bioengineered. https://doi.org/10.1080/21655979.2026.2667569

Source records